Daftar Pustaka

1. Ryan DJ, Lovin N, Furgiuele D, Johnson J, Egol K. Regional anesthesia for clavicle fracture surgery is safe and effective. Journal of Shoulder and Elbow Surgery. 2020.

2. Lowe JA, Fischer SJ. Clavicle fracture (broken collarbone). December 2016. Diunduh dari https://orthoinfo.aaos.org/en/diseases--conditions/clavicle-fracture-broken-collarbone/. 12 Januari 2022.

3. Euroespa. Superficial (and Intermediate) Cervical Plexus Block. 2014. Diunduh dari https://www.euroespa.com/wp-content/uploads/2014/10/SCPB-article-1.pdf. 12 Januari 2022.

4. Yao Y, Lin C, He Q, Gao H, Jin L, Zheng X. Ultrasound-guided bilateral superficial cervical plexus blocks enhance the quality of recovery in patients undergoing thyroid cancer surgery: a randomized controlled trial. Journal of Clinical Anesthesia, 2019.

5. Kanthan RK. The use of superficial cervical plexus block in oral and maxillofacial surgical practice as an alternative to general anesthesia in selective cases. Ann Maxillofac Surg 2016;6:4-8.

6. Van Laarhoven JJEM, Hietbrink F, Ferree S, Gunninh AC, Houwert RM, Verleisdonk EMM, et al. Associated thoracic injury in patients with a clavicle fracture: a retrospective analysis of 1461 polytrauma patients. Eur J Trauma Emerg Surg. 2016.

7. Nathe T, Tseng S, Yoo B. The anatomy of the supraclavicular nerve during surgical approach to the clavicular shaft. Clin Orthop Relat Res (2011) 469:890–894.

8. Tran DQH, Tiyaprasertkul W, Gonzalez AP. Analgesia for clavicular fracture and surgery. Regional Anesthesia and Pain Medicine. 2013; 38 (6):539-543.

9. Saranteas T, Kostroglou A, Efstathiou G, Giannoulis D, Moschovaki N, Mavrogenis AF, et al. Peripheral nerve blocks in the cervical region: from

anatomy to ultrasound – guided techniques. Dentomaxillofacial Radiology (2020) 49.

10. Vloka JD, Smeets AS, Tsai T, Bouts C. Cervical plexus block – landmarks and nerve stimulator technique. 2022. Diunduh dari https://www.nysora.com/techniques/head-and-neck-blocks/cervical/cervical-plexus-block/. 12 Januari 2022.

11. Rasa SN, Carr BD, Cohen M, Finnerup NB, Flor H, Gibson S, dkk. The revised internation association for the study of pain definition of pain: concepts, challenges, and compromises. Pain. 2020:161(9);1976-82.

12. International Association for the study of pain. IASP's proposed new difinition of pain release for comment. 2019. Diunduh dari https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=10475. 12 Januari 2022.

13. Joshi GP, Ogunnaike BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiol Clin North Am. 2005;23(1):21-36.

14. Brennan TJ, Pogatzki-Zahn EM. Pathophysiology of acute postoperative pain. 2017;3: 3–6.

15. Macres SM, Moore PG, Fishman SM. Acute pain management In : Paul G. Barash, eds. Clinical anesthesia, 8th ed. Philadelphia: Wolters Kluwer Health.p.3923-4.

16. Wainger BJ, Brenner GJ. Mechanisms of chronic pain. in: David E. Longnecker. Anesthesiology. 3rd ed. New York: McGraw-Hill. 2018.p.1446-7.

17. Jour, Dureja G, Iyer R, Das G, Ahdal J, Narang P. Evidence and consensus recommendations for the pharmacological management of pain in India. Journal of Pain Research: 2017; 10.

18. Macres SM, Moore PG, Fishman SM. Acute pain management. In: Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC, Orthega R, Sharar SR, Holt NF. Clinical anesthesia. 8th ed. Philadelphia: Wolters Kluwer; 2017.p.3919-32.

19. Lavand'homme P. From preemptive to preventive analgesia: time to reconsider the role of perioperative peripheral nerve block?. Reg Anesth Pain med. 2011;36(1)4-6.

20. Hipskind JE, Ahmed AA. Cervical plexus block. 31 Juli 2021. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Diunduh dari https://www.ncbi.nlm.nih.gov/books/NBK557382/. 31 Januari 2022.

21. Elsharkawy H, Naguib MA. Peripherally acting analgesic. In: Flood P, Rathmell JP, Shafer S. Stoelting's pharmacology & physiology in anesthetic practice. 5th ed. Philadelphia: Wolters Kluwer; 2015.p.282-7.

22. Chen LL, Mao J. Nonopioid pain medication. In: Gropper MA, Cohen NH, Eriksson LI, Fleisher LA, Leslie K, Wiener-Kronish JP, et al. Miller's anesthesia. 9th ed. Philadelphia : Elsevier; 2019.p.877-8.

23. Tegeder I. COX-1 and COX-2 in pain. In: Gebhart G.F., Schmidt R.F, et al. Encyclopedia of pain. Berlin: Springer; 2013.

24. Erlangga ME, Sitanggang RH, Bisri T. Perbandingan pemberian deksametason 10 mg dengan 15 mg intravena sebagai adjuvan analgetik terhadap skala nyeri paskabedah pada pasien yang dilakukan radical mastektomi termodifikasi. JAP. 2015;3(3):146-54.

25. Shahraki AD, Feizi A, Jabalameli M, Nouri S. The effect of intravenous dexamethasone on post-cesarean section pain and vital sign: a double-blind randomized clinical trial. J Res Pharm Pract. 2013;2(3):99-104.

26. Vandevyer S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology, March 2013, 154(3):993–1007

27. Butterworth JF, Mackey DC, Wasnick JD. Morgan & Mikhail's Clinical anesthesiology. 6th Ed. New York: Mcgraw Hill.p.187-471.

28. *The American Society of Health-System Pharmacists.* Lidocaine Hydrochloride (Local). 6 September 2015.

29. *J. P. Nolan, P. J. F. Baskett.* Analgesia and anaesthesia. *In David Skinner; Andrew Swain; Rodney Peyton; Colin Robertson, et al. Cambridge*

Textbook of Accident and Emergency Medicine. UK: Cambridge University Press; 1997.p.194.

30. Maheshwari K. Naguib MA. Local anesthetics. In: Flood P, Rathmell JP, Shafer S. Stoelting's pharmacology & physiology in anesthetic practice. 5th Ed. USA: Wolters Kluwer; 2015.p.282-313.

31. Foster RH, Markham A. Levobupivacaine: A review of its pharmacology and use as a local anaesthetic. Drugs 2000 Mar; 59 (3): 551-579.

32. Cumming KI, Naguib MA. Opioid agonist and antagonist. In: Flood P, Rathmell JP, Shafer S, et al. Pharmacology and physiology in anesthetic practice. 5th ed. Philadephia: Wolters Kluwer; 2015.p.217-50.

33. Daniel M, Weiskopf RB, Noorani M. Fentanyl augments the blockade of the sympathetic response to incision (MAC-BAR) produced by desflurane and isoflurane: desflurane and isoflurane MAC-BAR without and with fentanyl. Anesthesiology. 1998; 88: 43–49.

34. Becker LD, Paulson BA, Miller RD, Severinghaus JW, Eger EI. Biphasic respiratory depression after fentanyl - droperidol or fentanyl alone used to supplement nitrous oxide anesthesia. Anesthesiology. 1976; 44:291–295.

35. Flood P, Shafer S. Inhales anesthetics. In: Flood P, Rathmess JP, Shafer S, et al. Stoelting's pharmacology & physiology in anesthetic practice. 5th Ed. Philadelphia: Wolters Kluwer; 2015.p.98-152.

36. Perouansky M, Pearce RA, Hemmings H, Franks NP. Inhaled anesthetics: mechanism of action. In: Gropper MA, Cohen NH, Eriksson LI, Fleisher LA, Leslie K, Kronish, JPW, eds. Miller's anesthesia. 9th ed. Philadelphia: Elsevier; 2019.p.487-506.

37. Marthur S, Patel J, Goldstein S, Jain A. Bispectral Index. 21 September 2021. Diunduh dari https://www.ncbi.nlm.nih.gov/books/NBK539809. 21 Januari 2022.

38. Larson MD, Behrends M. Portable infrared pupillometri: a review. International Anesthesia Research Society. 2015; 120 (6).

39. Packiasabapathy S, Rangasamy V, Sadhasivam S. Pupillometri in perioperative medicine: a narrative review. Can J Anesth/J Can Anesth (2021) 68:566–578.

40. Kim JH, Jwa EK, Choung Y, Yeon HJ, Kim SY, Kim E. Cpmarison of pupillometri with surgical pleth index monitoring on perioperative opioid consumption and nociception during propofol – remifentanil anesthesia: a prospective randomized controlled trial. International Anesthesia Research Society. 2020. 131 (5).

41. Bourgeois E, Sabourdin N, Louvet N, Donette FX, Guye ML, Constant I. Minimal alveolar concentration of sevoflurane inhibiting the reflex pupillary dilatation after noxious stimulation in children and young adults. British Journal of Anaesthesia 108 (4): 648–54 (2012).

42. Idmed. Algiscan: pupillary algesimeter. 2019. Diunduh dari https://www.idmed.fr/en/analgesia/. 9 April 2022.

43. Berthoud V, Nguyen M, Appriou A, Ellouze O, Radhouani M, Constandache T, et al. Pupillometri pain index decreases intraoperative sufentanil administration in cardiac surgery: a prospective randomized study. Scientifc Reports (2020) 10:21056.

44. Pryambodho, Margaretha RE, Tantri AR, Priyono H. Peran blok servikalis superfisialis pada timpanomastoidektomi dalam anestesia umum. ORLI Vol. 45 No. 1 Tahun 2015.

45. Arjun BK, Vinod CN, Puneeth J, Narendrababu MC. Ultrasound-guided interscalene block combined with intermediate or superficial cervical plexus block for clavicle surgery. Eur J Anaesthesiol 2020; 37:979–983.

46. Shanthanna H. Ultraound guided selective cervical nerve root block and superficial cervical plexus block for surgeries on the clavicle. Indian J Anaesth 2014; 58:327-9.

47. Merah. Casati L, Galinski SF, Barrera E, Pol O, Puig MM. Isoflurane requirements during combined general/epidural anesthesia for major abdominal surgery. Anesth Analg. 2002 May;94(5):1331-7

48. Pandit JJ, Dutta D, Morris JF. Spread of injectate with superficial cervical plexus block in humans: an anatomical study. British Journal of Anaesthesia 91 (5): 733±5 (2003).

49. Hannadige H. A complication of superficial cervical plexus block used for thyroidectomy. Article in Sri Lankan Journal of Anaesthesiology · July 2015.

50. Shih ML, Duh QY, Hsieh CB, Liu YC, Lu CH, Wong CS, Yu JC, Yeh CC. Bilateral superficial cervical plexus block combined with general anesthesia administered in thyroid operations. World J Surg (2010) 34:2338–2343.

51. Urbanek B, Duma A, Kimberger O, Huber G, Marhofer P, Zimpfer M, Kapral S. Onset time, quality of blockade, and duration of three-in-one blocks with levobupivacaine and bupivacaine. Anesth Analg 2003; 97:888 –92.

52. Eti Z, Irmak P, Gulluoglu BM, Manukyan MN, Gogus FY. Does bilateral superficial cervical plexus block decrease analgesic requirement after thyroid surgery?. Anesth Analg 2006; 102:1174–6.

53. Johnson Q, Borsheski RR, Reeves-Viets JL. A review of management of acute pain. Mo Med. 2013 Jan-Feb; 110(1): 74–79.

Lampiran 1. Analisis Data

Kelompok * JenisKelamin Crosstabulation

Count

		JenisKelamin		Total
		Laki - Laki	Perempuan	
Kelompok	Kelompok Kontrol	13	2	15
	Kelompok Perlakuan	13	2	15
Total		26	4	30

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.000[a]	1	1.000		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.000	1	1.000		
Fisher's Exact Test				1.000	.701
Linear-by-Linear Association	.000	1	1.000		
N of Valid Cases	30				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.00.

b. Computed only for a 2x2 table

Tests of Normality

	Kelompok	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Umur	Kelompok Kontrol	.224	15	.042	.909	15	.130
	Kelompok Perlakuan	.193	15	.137	.902	15	.102
BB	Kelompok Kontrol	.187	15	.165	.924	15	.224
	Kelompok Perlakuan	.192	15	.143	.887	15	.060
TB	Kelompok Kontrol	.173	15	.200*	.948	15	.501
	Kelompok Perlakuan	.182	15	.195	.954	15	.585
IMT	Kelompok Kontrol	.121	15	.200*	.961	15	.707
	Kelompok Perlakuan	.202	15	.102	.916	15	.167
LamaOperasi	Kelompok Kontrol	.147	15	.200*	.933	15	.304
	Kelompok Perlakuan	.131	15	.200*	.972	15	.882

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
Umur	Based on Mean	.322	1	28	.575
	Based on Median	.092	1	28	.764
	Based on Median and with adjusted df	.092	1	24.008	.765
	Based on trimmed mean	.288	1	28	.596
BB	Based on Mean	1.398	1	28	.247
	Based on Median	.876	1	28	.357
	Based on Median and with adjusted df	.876	1	27.413	.358
	Based on trimmed mean	1.240	1	28	.275
TB	Based on Mean	.616	1	28	.439
	Based on Median	.638	1	28	.431
	Based on Median and with adjusted df	.638	1	27.846	.431
	Based on trimmed mean	.542	1	28	.468
IMT	Based on Mean	.078	1	28	.783
	Based on Median	.129	1	28	.722
	Based on Median and with adjusted df	.129	1	26.569	.722
	Based on trimmed mean	.093	1	28	.763
LamaOperasi	Based on Mean	.294	1	28	.592
	Based on Median	.331	1	28	.570
	Based on Median and with adjusted df	.331	1	27.920	.570
	Based on trimmed mean	.318	1	28	.577

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means					95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Umur	Equal variances assumed	.322	.575	-.138	28	.892	-.73333	5.32958	-11.65049	10.18382
	Equal variances not assumed			-.138	27.736	.892	-.73333	5.32958	-11.65518	10.18851
BB	Equal variances assumed	1.398	.247	-.055	28	.956	-.20000	3.62732	-7.63023	7.23023
	Equal variances not assumed			-.055	26.105	.956	-.20000	3.62732	-7.65460	7.25460
TB	Equal variances assumed	.616	.439	-.186	28	.854	-.46667	2.51156	-5.61137	4.67803
	Equal variances not assumed			-.186	27.563	.854	-.46667	2.51156	-5.61504	4.68171
IMT	Equal variances assumed	.078	.783	-.105	28	.917	-.09727	.92921	-2.00066	1.80613
	Equal variances not assumed			-.105	27.990	.917	-.09727	.92921	-2.00069	1.80616
LamaOperasi	Equal variances assumed	.294	.592	2.176	28	.038	24.66667	11.33543	1.44708	47.88625
	Equal variances not assumed			2.176	27.799	.038	24.66667	11.33543	1.43950	47.89383

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Kelompok	Statistic	df	Sig.	Statistic	df	Sig.
SistoleDasar	Kelompok Kontrol	.173	15	.200*	.881	15	.049
	Kelompok Perlakuan	.192	15	.140	.950	15	.532
SistoleInsisi	Kelompok Kontrol	.295	15	.001	.819	15	.006
	Kelompok Perlakuan	.218	15	.054	.936	15	.340
SistolePeriosteum	Kelompok Kontrol	.226	15	.039	.857	15	.022
	Kelompok Perlakuan	.331	15	.000	.815	15	.006
DiastoleDasar	Kelompok Kontrol	.190	15	.149	.855	15	.020
	Kelompok Perlakuan	.225	15	.039	.916	15	.169
DiastoleInsisi	Kelompok Kontrol	.340	15	.000	.710	15	.000
	Kelompok Perlakuan	.285	15	.002	.809	15	.005
DiastolePeriosteum	Kelompok Kontrol	.169	15	.200*	.880	15	.048
	Kelompok Perlakuan	.264	15	.006	.829	15	.009
MAPDasar	Kelompok Kontrol	.179	15	.200*	.838	15	.012
	Kelompok Perlakuan	.206	15	.088	.850	15	.017
MAPInsisi	Kelompok Kontrol	.363	15	.000	.710	15	.000
	Kelompok Perlakuan	.259	15	.008	.817	15	.006
MAPPeriosteum	Kelompok Kontrol	.200	15	.108	.879	15	.045
	Kelompok Perlakuan	.223	15	.043	.834	15	.010
LajuJantungDasar	Kelompok Kontrol	.207	15	.084	.886	15	.057
	Kelompok Perlakuan	.152	15	.200*	.953	15	.570
LajuJantungInsisi	Kelompok Kontrol	.202	15	.099	.843	15	.014
	Kelompok Perlakuan	.284	15	.002	.742	15	.001
LajuJantungPeriosteum	Kelompok Kontrol	.183	15	.190	.906	15	.119
	Kelompok Perlakuan	.171	15	.200*	.921	15	.201

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
SistoleDasar	Based on Mean	.157	1	28	.695
	Based on Median	.137	1	28	.714
	Based on Median and with adjusted df	.137	1	26.732	.714
	Based on trimmed mean	.171	1	28	.682
SistoleInsisi	Based on Mean	2.939	1	28	.098
	Based on Median	2.730	1	28	.110
	Based on Median and with adjusted df	2.730	1	17.250	.117
	Based on trimmed mean	2.763	1	28	.108
SistolePeriosteum	Based on Mean	29.533	1	28	.000
	Based on Median	9.457	1	28	.005
	Based on Median and with adjusted df	9.457	1	22.341	.005
	Based on trimmed mean	28.790	1	28	.000
DiastoleDasar	Based on Mean	2.014	1	28	.167
	Based on Median	1.003	1	28	.325
	Based on Median and with adjusted df	1.003	1	23.306	.327
	Based on trimmed mean	1.838	1	28	.186
DiastoleInsisi	Based on Mean	1.155	1	28	.292
	Based on Median	.537	1	28	.470
	Based on Median and with adjusted df	.537	1	23.516	.471
	Based on trimmed mean	.746	1	28	.395
DiastolePeriosteum	Based on Mean	29.477	1	28	.000
	Based on Median	23.108	1	28	.000
	Based on Median and with adjusted df	23.108	1	25.421	.000
	Based on trimmed mean	29.208	1	28	.000
MAPDasar	Based on Mean	.035	1	28	.853
	Based on Median	.026	1	28	.873
	Based on Median and with adjusted df	.026	1	27.250	.873
	Based on trimmed mean	.004	1	28	.949

MAPInsisi	Based on Mean	2.976	1	28	.096
	Based on Median	1.366	1	28	.252
	Based on Median and with adjusted df	1.366	1	18.057	.258
	Based on trimmed mean	1.923	1	28	.176
MAPPeriosteum	Based on Mean	28.534	1	28	.000
	Based on Median	11.838	1	28	.002
	Based on Median and with adjusted df	11.838	1	21.833	.002
	Based on trimmed mean	27.951	1	28	.000
LajuJantungDasar	Based on Mean	2.699	1	28	.112
	Based on Median	2.371	1	28	.135
	Based on Median and with adjusted df	2.371	1	25.957	.136
	Based on trimmed mean	2.664	1	28	.114
LajuJantungInsisi	Based on Mean	.940	1	28	.341
	Based on Median	.435	1	28	.515
	Based on Median and with adjusted df	.435	1	27.970	.515
	Based on trimmed mean	.867	1	28	.360
LajuJantungPeriosteum	Based on Mean	28.480	1	28	.000
	Based on Median	20.956	1	28	.000
	Based on Median and with adjusted df	20.956	1	22.689	.000
	Based on trimmed mean	28.969	1	28	.000

Test Statistics[a]

	SistoleDasar	SistoleInsisi	SistolePeriosteum	DiastoleDasar	DiastoleInsisi	DiastolePeriosteum	MAPDasar	MAPInsisi	MAPPeriosteum	LajuJantungDasar	LajuJantungInsisi	LajuJantungPeriosteum
Mann-Whitney U	99.000	47.500	99.500	105.000	65.500	89.500	80.500	62.000	92.000	111.500	51.000	54.500
Wilcoxon W	219.000	167.500	219.500	225.000	185.500	209.500	200.500	182.000	212.000	231.500	171.000	174.500
Z	-.565	-2.708	-.542	-.316	-1.973	-.961	-1.337	-2.112	-.852	-.042	-2.561	-2.409
Asymp. Sig. (2-tailed)	.572	.007	.588	.752	.048	.336	.181	.035	.394	.967	.010	.016
Exact Sig. [2*(1-tailed Sig.)]	.595[b]	.006[b]	.595[b]	.775[b]	.050[b]	.345[b]	.187[b]	.037[b]	.412[b]	.967[b]	.010[b]	.015[b]

a. Grouping Variable: Kelompok

b. Not corrected for ties.

Test Statistics[a]

Kelompok		SistoleInsisi - SistoleDasar	SistolePeriosteum - SistoleDasar	DiastoleInsisi - DiastoleDasar	DiastolePeriosteum - DiastoleDasar	MAPInsisi - MAPDasar	MAPPeriosteum - MAPDasar	LajuJantungInsisi - LajuJantungDasar	LajuJantungPeriosteum - LajuJantungDasar
Kelompok Kontrol	Z	-2.481[b]	-1.994[b]	-1.458[c]	-2.031[b]	-1.311[c]	-2.133[b]	-3.193[b]	-2.639[b]
	Asymp. Sig. (2-tailed)	.013	.046	.145	.042	.190	.033	.001	.008
Kelompok Perlakuan	Z	-1.226[c]	-.256[c]	-.070[b]	-1.068[b]	-1.247[c]	-.553[c]	.000[d]	-1.074[c]
	Asymp. Sig. (2-tailed)	.220	.798	.944	.285	.213	.580	1.000	.283

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.

c. Based on positive ranks.

d. The sum of negative ranks equals the sum of positive ranks.

Tests of Normality

	Kelompok	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Fentanyl	Kelompok Kontrol	.323	15	.000	.793	15	.003
	Kelompok Perlakuan	.535	15	.000	.284	15	.000
JumlahFentanyl	Kelompok Kontrol	.270	15	.004	.827	15	.008
	Kelompok Perlakuan	.535	15	.000	.284	15	.000

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
Fentanyl	Based on Mean	8.292	1	28	.008
	Based on Median	7.865	1	28	.009
	Based on Median and with adjusted df	7.865	1	16.373	.013
	Based on trimmed mean	7.943	1	28	.009
JumlahFentanyl	Based on Mean	9.079	1	28	.005
	Based on Median	9.677	1	28	.004
	Based on Median and with adjusted df	9.677	1	17.152	.006
	Based on trimmed mean	9.422	1	28	.005

Test Statistics[a]

	Fentanyl	JumlahFentanyl
Mann-Whitney U	43.500	44.500
Wilcoxon W	163.500	164.500
Z	-3.355	-3.268
Asymp. Sig. (2-tailed)	.001	.001
Exact Sig. [2*(1-tailed Sig.)]	.003[b]	.004[b]

a. Grouping Variable: Kelompok

b. Not corrected for ties.

Tests of Normality

	Kelompok	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Isofluran	Kelompok Kontrol	.348	15	.000	.796	15	.003
	Kelompok Perlakuan	.116	15	.200*	.974	15	.917

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
Isofluran	Based on Mean	3.410	1	28	.075
	Based on Median	.352	1	28	.557
	Based on Median and with adjusted df	.352	1	21.194	.559
	Based on trimmed mean	3.318	1	28	.079

Correlations

	Kelompok			Isofluran	LamaOperasi	JumlahFentanyl
Spearman's rho	Kelompok Kontrol	Isofluran	Correlation Coefficient	1.000	.246	-.013
			Sig. (2-tailed)	.	.377	.964
			N	15	15	15
		LamaOperasi	Correlation Coefficient	.246	1.000	.584*
			Sig. (2-tailed)	.377	.	.022
			N	15	15	15
		JumlahFentanyl	Correlation Coefficient	-.013	.584*	1.000
			Sig. (2-tailed)	.964	.022	.
			N	15	15	15
	Kelompok Perlakuan	Isofluran	Correlation Coefficient	1.000	.154	.310
			Sig. (2-tailed)	.	.584	.260
			N	15	15	15
		LamaOperasi	Correlation Coefficient	.154	1.000	.435
			Sig. (2-tailed)	.584	.	.105
			N	15	15	15
		JumlahFentanyl	Correlation Coefficient	.310	.435	1.000
			Sig. (2-tailed)	.260	.105	.
			N	15	15	15

*. Correlation is significant at the 0.05 level (2-tailed).

Tests of Normality

	Kelompok	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
NRSdiam2	Kelompok Kontrol	.300	15	.001	.806	15	.004
	Kelompok Perlakuan	.305	15	.001	.766	15	.001
NRSdiam4	Kelompok Kontrol	.238	15	.022	.817	15	.006
	Kelompok Perlakuan	.340	15	.000	.758	15	.001
NRSdiam6	Kelompok Kontrol	.419	15	.000	.603	15	.000
	Kelompok Perlakuan	.425	15	.000	.631	15	.000
NRSdiam12	Kelompok Kontrol	.419	15	.000	.603	15	.000
	Kelompok Perlakuan	.514	15	.000	.413	15	.000
NRSdiam24	Kelompok Kontrol	.453	15	.000	.561	15	.000
	Kelompok Perlakuan	.367	15	.000	.716	15	.000
NRSgerak2	Kelompok Kontrol	.277	15	.003	.739	15	.001
	Kelompok Perlakuan	.350	15	.000	.643	15	.000
NRSgerak4	Kelompok Kontrol	.249	15	.013	.806	15	.004
	Kelompok Perlakuan	.350	15	.000	.643	15	.000
NRSgerak6	Kelompok Kontrol	.425	15	.000	.631	15	.000
	Kelompok Perlakuan	.453	15	.000	.561	15	.000
NRSgerak12	Kelompok Kontrol	.485	15	.000	.499	15	.000
	Kelompok Perlakuan	.514	15	.000	.413	15	.000
NRSgerak24	Kelompok Kontrol	.453	15	.000	.561	15	.000
	Kelompok Perlakuan	.419	15	.000	.603	15	.000

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
NRSdiam2	Based on Mean	.444	1	28	.510
	Based on Median	.759	1	28	.391
	Based on Median and with adjusted df	.759	1	25.321	.392
	Based on trimmed mean	.550	1	28	.465
NRSdiam4	Based on Mean	.407	1	28	.529
	Based on Median	.509	1	28	.481
	Based on Median and with adjusted df	.509	1	27.991	.481
	Based on trimmed mean	.384	1	28	.541
NRSdiam6	Based on Mean	3.382	1	28	.077
	Based on Median	.651	1	28	.426
	Based on Median and with adjusted df	.651	1	27.277	.427
	Based on trimmed mean	2.935	1	28	.098
NRSdiam12	Based on Mean	7.338	1	28	.011
	Based on Median	1.658	1	28	.208
	Based on Median and with adjusted df	1.658	1	25.461	.209
	Based on trimmed mean	7.338	1	28	.011
NRSdiam24	Based on Mean	.910	1	28	.348
	Based on Median	.000	1	28	1.000
	Based on Median and with adjusted df	.000	1	28.000	1.000
	Based on trimmed mean	.712	1	28	.406
NRSgerak2	Based on Mean	3.868	1	28	.059
	Based on Median	2.930	1	28	.098
	Based on Median and with adjusted df	2.930	1	24.962	.099
	Based on trimmed mean	3.985	1	28	.056
NRSgerak4	Based on Mean	1.869	1	28	.182
	Based on Median	.509	1	28	.481
	Based on Median and with adjusted df	.509	1	27.991	.481
	Based on trimmed mean	2.062	1	28	.162

NRSgerak6	Based on Mean	1.607	1	28	.215
	Based on Median	.175	1	28	.679
	Based on Median and with adjusted df	.175	1	27.723	.679
	Based on trimmed mean	1.186	1	28	.285
NRSgerak12	Based on Mean	.924	1	28	.345
	Based on Median	.226	1	28	.638
	Based on Median and with adjusted df	.226	1	27.290	.638
	Based on trimmed mean	.924	1	28	.345
NRSgerak24	Based on Mean	.592	1	28	.448
	Based on Median	.149	1	28	.702
	Based on Median and with adjusted df	.149	1	27.886	.702
	Based on trimmed mean	.592	1	28	.448

Test Statistics[a]

	NRSdiam2	NRSdiam4	NRSdiam6	NRSdiam12	NRSdiam24	NRSgerak2	NRSgerak4	NRSgerak6	NRSgerak12	NRSgerak24
Mann-Whitney U	28.500	31.000	40.000	90.000	86.500	24.500	21.000	79.000	105.000	105.000
Wilcoxon W	148.500	151.000	160.000	210.000	206.500	144.500	141.000	199.000	225.000	225.000
Z	-3.688	-3.614	-3.429	-1.273	-1.395	-3.903	-4.019	-1.882	-.482	-.392
Asymp. Sig. (2-tailed)	.000	.000	.001	.203	.163	.000	.000	.060	.630	.695
Exact Sig. [2*(1-tailed Sig.)]	.000[b]	.000[b]	.002[b]	.367[b]	.285[b]	.000[b]	.000[b]	.174[b]	.775[b]	.775[b]

a. Grouping Variable: Kelompok

b. Not corrected for ties.

121

Correlations

	Kelompok			NRSdiam2	NRSdiam4	NRSdiam6	LamaOperasi
Spearman's rho	Kelompok Kontrol	NRSdiam2	Correlation Coefficient	1.000	.536*	.670**	.492
			Sig. (2-tailed)	.	.040	.006	.062
			N	15	15	15	15
		NRSdiam4	Correlation Coefficient	.536*	1.000	.884**	.430
			Sig. (2-tailed)	.040	.	.000	.110
			N	15	15	15	15
		NRSdiam6	Correlation Coefficient	.670**	.884**	1.000	.608*
			Sig. (2-tailed)	.006	.000	.	.016
			N	15	15	15	15
		LamaOperasi	Correlation Coefficient	.492	.430	.608*	1.000
			Sig. (2-tailed)	.062	.110	.016	.
			N	15	15	15	15
	Kelompok Perlakuan	NRSdiam2	Correlation Coefficient	1.000	.895**	.625*	.017
			Sig. (2-tailed)	.	.000	.013	.951
			N	15	15	15	15
		NRSdiam4	Correlation Coefficient	.895**	1.000	.682**	-.137
			Sig. (2-tailed)	.000	.	.005	.627
			N	15	15	15	15
		NRSdiam6	Correlation Coefficient	.625*	.682**	1.000	.264
			Sig. (2-tailed)	.013	.005	.	.343
			N	15	15	15	15
		LamaOperasi	Correlation Coefficient	.017	-.137	.264	1.000
			Sig. (2-tailed)	.951	.627	.343	.
			N	15	15	15	15

*. Correlation is significant at the 0.05 level (2-tailed).

**. Correlation is significant at the 0.01 level (2-tailed).

122

Nonparametric Correlations

Correlations

	Kelompok			LamaOperasi	NRSgerak2	NRSgerak4
Spearman's rho	Kelompok Kontrol	LamaOperasi	Correlation Coefficient	1.000	.430	.277
			Sig. (2-tailed)	.	.110	.318
			N	15	15	15
		NRSgerak2	Correlation Coefficient	.430	1.000	.559*
			Sig. (2-tailed)	.110	.	.030
			N	15	15	15
		NRSgerak4	Correlation Coefficient	.277	.559*	1.000
			Sig. (2-tailed)	.318	.030	.
			N	15	15	15
	Kelompok Perlakuan	LamaOperasi	Correlation Coefficient	1.000	.358	.358
			Sig. (2-tailed)	.	.191	.191
			N	15	15	15
		NRSgerak2	Correlation Coefficient	.358	1.000	1.000**
			Sig. (2-tailed)	.191	.	.
			N	15	15	15
		NRSgerak4	Correlation Coefficient	.358	1.000**	1.000
			Sig. (2-tailed)	.191	.	.
			N	15	15	15

*. Correlation is significant at the 0.05 level (2-tailed).

**. Correlation is significant at the 0.01 level (2-tailed).

Tests of Normality

	Kelompok	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
WRA2	Kelompok Kontrol	.453	15	.000	.561	15	.000
	Kelompok Perlakuan	.	15	.	.	15	.
WRA4	Kelompok Kontrol	.485	15	.000	.499	15	.000
	Kelompok Perlakuan	.	15	.	.	15	.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
WRA2	Based on Mean	50.286	1	28	.000
	Based on Median	5.091	1	28	.032
	Based on Median and with adjusted df	5.091	1	14.000	.041
	Based on trimmed mean	38.250	1	28	.000
WRA4	Based on Mean	24.889	1	28	.000
	Based on Median	3.500	1	28	.072
	Based on Median and with adjusted df	3.500	1	14.000	.082
	Based on trimmed mean	17.719	1	28	.000

Kelompok * WRA2

Crosstab

Count

		WRA2		
		Tidak	Ya	Total
Kelompok	Kelompok Kontrol	10	5	15
	Kelompok Perlakuan	15	0	15
Total		25	5	30

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	6.000[a]	1	.014		
Continuity Correction[b]	3.840	1	.050		
Likelihood Ratio	7.938	1	.005		
Fisher's Exact Test				.042	.021
Linear-by-Linear Association	5.800	1	.016		
N of Valid Cases	30				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.50.

b. Computed only for a 2x2 table

Kelompok * WRA4

Crosstab

Count

		WRA4		Total
		Tidak	Ya	
Kelompok	Kelompok Kontrol	10	5	15
	Kelompok Perlakuan	15	0	15
Total		25	5	30

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	6.000[a]	1	.014		
Continuity Correction[b]	3.840	1	.050		
Likelihood Ratio	7.938	1	.005		
Fisher's Exact Test				.042	.021
Linear-by-Linear Association	5.800	1	.016		
N of Valid Cases	30				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.50.

b. Computed only for a 2x2 table

➡ **Nonparametric Correlations**

Correlations

	Kelompok				LamaOperasi	WRA2	WRA4
Spearman's rho	Kelompok Kontrol	LamaOperasi	Correlation Coefficient		1.000	.210	.000
			Sig. (2-tailed)		.	.452	1.000
			N		15	15	15
		WRA2	Correlation Coefficient		.210	1.000	-.302
			Sig. (2-tailed)		.452	.	.275
			N		15	15	15
		WRA4	Correlation Coefficient		.000	-.302	1.000
			Sig. (2-tailed)		1.000	.275	.
			N		15	15	15
	Kelompok Perlakuan	LamaOperasi	Correlation Coefficient		1.000	.	.
			Sig. (2-tailed)		.	.	.
			N		15	15	15
		WRA2	Correlation Coefficient		.	.	.
			Sig. (2-tailed)		.	.	.
			N		15	15	15
		WRA4	Correlation Coefficient		.	.	.
			Sig. (2-tailed)		.	.	.
			N		15	15	15

Tests of Normality

	Kelompok	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
RescueFentanyl	Kelompok Kontrol	.350	15	.000	.643	15	.000
	Kelompok Perlakuan	.	15	.	.	15	.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
RescueFentanyl	Based on Mean	3136.000	1	28	.000
	Based on Median	12.250	1	28	.002
	Based on Median and with adjusted df	12.250	1	14.000	.004
	Based on trimmed mean	2537.641	1	28	.000

Mann-Whitney Test

Ranks

	Kelompok	N	Mean Rank	Sum of Ranks
RescueFentanyl	Kelompok Kontrol	15	19.00	285.00
	Kelompok Perlakuan	15	12.00	180.00
	Total	30		

Test Statistics[a]

	RescueFentanyl
Mann-Whitney U	60.000
Wilcoxon W	180.000
Z	-2.971
Asymp. Sig. (2-tailed)	.003
Exact Sig. [2*(1-tailed Sig.)]	.029[b]

a. Grouping Variable: Kelompok

b. Not corrected for ties.

→ Nonparametric Correlations

Correlations

	Kelompok			LamaOperasi	RescueFentanyl
Spearman's rho	Kelompok Kontrol	LamaOperasi	Correlation Coefficient	1.000	.186
			Sig. (2-tailed)	.	.506
			N	15	15
		RescueFentanyl	Correlation Coefficient	.186	1.000
			Sig. (2-tailed)	.506	.
			N	15	15
	Kelompok Perlakuan	LamaOperasi	Correlation Coefficient	1.000	.
			Sig. (2-tailed)	.	.
			N	15	15
		RescueFentanyl	Correlation Coefficient	.	.
			Sig. (2-tailed)	.	.
			N	15	15

PERSETUJUAN SETELAH PENJELASAN

PENGARUH BLOK PLEKSUS SERVIKAL SUPERFISIALIS MENGGUNAKAN LEVOBUPIVAKAIN ISOBARIK 0,25% TERHADAP KESTABILAN HEMODINAMIK DAN KEBUTUHAN OBAT ANESTESI INTRAOPERATIF PADA PEMBEDAHAN REGIO KLAVIKULA

Yang bertandatangan dibawah ini:

Nama/Umur   :

A l a m a t   :

No. Rekam Medis   :

Menyatakan dengan sesungguhnya bahwa saya telah mendapatkan penjelasan dan kesempatan bertanya hal-hal yang belum saya mengerti tentang penelitian ini. Penjelasan tersebut meliputi manfaat dan keuntungan serta efek samping dari tindakan injeksi levobupivakain di ruang operasi, yang akan diberikan pada saya dalam penelitian ini.

Secara teoritis, perlakuan pemberian injeksi levobupivakain dalam dosis ini aman dan memiliki efek samping dan komplikasi yang minimal. Meskipun demikian efek samping dan komplikasi bisa saja terjadi tanpa bisa diprediksi sebelumnya. Efek samping dan komplikasi yang mungkin timbul dari injeksi levobupivakain adalah alergi, gelisah, pusing, kebingungan, adanya kebas di lidah, terasa logam, depresi pernafasan, kejang, penglihatan kabur, tinnitus, kejang, hipotensi, dan aritmia jantung. Bila terjadi hal demikian peneliti akan memberikan obat-obatan dan melakukan tindakan untuk menangani efek samping dan komplikasi tersebut.

Setelah mendapat penjelasan tersebut, dengan ini saya menyatakan saya secara sukarela ikut serta dalam penelitian ini dan berhak mengundurkan diri bila ada alasan sehubungan dengan kesehatan saya. Demikian pula jika terjadi ketidaksesuaian, saya akan

menelaah kembali untuk mencari jalan keluar yang terbaik tentang ketidaksesuaian tersebut.

Demikian pernyataan ini saya buat dengan sebenarnya, dengan penuh kesadaran dan tanpa paksaan.

Makassar,   2022

Saksi,   <u>Tanda Tangan</u>   Yang Menyatakan,

1.   ……………………….....................

2.   …………………………………….....

(…………………....)

Penanggung Jawab Medik,
dr. Wahyudi, Sp. An - KAP
0811446112

Jl. Hertasning Barat II, GPI C-9

Makassar

Penanggung Jawab Penelitian,
dr. Anthony Hadi Wibowo Tlp.
Tlp. 081288689980

Perintis Kemerdekaan XIV,

Tamalanrea Makassar

Lampiran 3. Case Report Form

Case Report Form

Nama	:	
No. RM	:	
Tgl.lahir/umur	:	
Berat badan	:	
Tinggi badan	:	
IMT	:	
Diagnosis	:	
Tindakan pembedahan	:	
VAS pre-op	:	
Opioid pre-op	:	
ASA PS kelas	:	
Jam mulai anestesi	:	
Jam mulai operasi	:	
Jam selesai anestesi	:	
Jam selesai operasi	:	
Lama pembedahan	: ……………jam ;…………………………menit	

P75

P50

Penilaian intraoperatif

Jam	Menit	RR	HR	TD	MAP	BIS	PPI	Fentanyl	Isoflurane	Keterangan (Insisi kulit/manipulasi periosteum)

Skor NRS & Waktu Rescue Analgesia

Jam	NRS		Rescue Fentanyl
	Diam	Gerak	
2			
4			
6			
12			
24			
Jumlah			

ADVERSE EVENT FORM

Identitas

Nama (Inisial) / Umur :

No. MR   :

Diagnosis   :

Adverse event

No.	Gejala	Berat	Ringan	Tidak Ada
1	Alergi			
2	Bradikardi			
3	Hipotensi			
4	Tanda Intoksikasi (gelisah, pusing, kebingungan, lidah kebas, lidah terasa logam, tinnitus, penglihatan kabur, depresi nafas, kejang, aritmia jantung)			

Penanganan *adverse event*

No.	Gejala	Penanganan
1	Alergi	Diberikan Diphenhidramin 10 mg/IV dan dexamethasone 5 mg/IV
2	Bradikardi	Diberikan Sulfas Atropin 0,01-0,02 mg/kgBB/ IV
3	Hipotensi	Diberikan Efedrin 5- 10 mg/IV
4	Tanda intoksikasi	Dilakukan resusitasi kardiopulmonal dan oksigenasi, diberikan lipid 20% 1,5 ml/kgBB selama 1 menit, diikuti infus kontinu 0,25 ml/kgBB/menit hingga setidaknya 10 menit setelah hemodinamik stabil. Jika hemodinamik belum tabil maka dapat diberikan bolus ulang kedua (maksimal dua kali) yang dilanjutkan dengan infus kontinu 0,5 ml/kgBB/menit.

Peneliti,

dr. Anthony Hadi Wibowo

Lampiran 5. Rekomendasi Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari..MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 288/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 17 Juni 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22050240	No Sponsor Protokol	
Peneliti Utama	**dr. Anthony Hadi Wibowo**	Sponsor	
Judul Peneliti	Pengaruh blok pleksus servikal superfisialis menggunakan levobupivakain isobarik 0,25% terhadap hemodinamik, kebutuhan obat anestesi, dan intensitas nyeri pada pembedahan regio klavikula		
No Versi Protokol	2	Tanggal Versi	**15 Juni 2022**
No Versi PSP	2	Tanggal Versi	**15 Juni 2022**
Tempat Penelitian	RS Wahidin Sudirohusodo Makassar		

Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal **15 Juni 2022**	Masa Berlaku **17 Juni 2022** sampai **17 Juni 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan